LOUISVILLE, Ky. -- Minimally invasive ablative therapy for early kidney cancer had an increased risk of local and metastatic ...

Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...

Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025- - Commercial Planning in Progress for 2025 Launch - - Late Breaker Poster Presentation ...

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting ...

Swedish battery manufacturer Northvolt, once the poster child of Europe’s green industry and battery ... place as among the ...

In an online-only poster (e-poster), the company will present ... are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed ...

About five percent of cancers are genetically linked. Lifestyle factors play an even greater role. So what can you do to cut your cancer risk? We answer a viewer question from Afghanistan.

Pharmacokinetic Results: TX45 demonstrated a potential best-in-class half-life for a long-acting relaxin therapy. Final analysis showed that a single dose of TX45 had approximately 50% subcutaneous ...

"Up until now, risk models in genomics have relied on broad categories that overlook the specific and unique genetic makeup of each individual," said Giordano Bottà, CEO of Allelica. "This innovation ...